Cancer pain can be related to the treatment of cancer by chemotherapy, and radiation therapy, among others. Cancer pain can also be caused by the pressing of the tumor onto the nerves, bones, or other organs of the body. Cancer pain can be categorized as acute and chronic based on the onset and duration of cancer. Acute cancer pains have an identifiable cause, well-defined onset, are subject to sympathetic output and improve with management. Acute cancer pain syndromes are caused by antineoplastic therapies such as chemotherapy, hormonal treatments, immunotherapy, and radiation therapy; procedures such as post-biopsy pain, stent placements, vascular embolization, and paracentesis, among others. Chronic cancer pain has a prolonged, and the fluctuating course has a less distinct onset and is driven by central sensitization and neuroplastic responses from acute injury. Chronic cancer pain syndromes are caused by somatic nociceptive pain due to soft tissue involvement, and bone metastases; and neuropathic pain due to malignancy.
Opioids are expected to remain the dominant drug class segment in cancer pain market, owing to their ability to effectively treat the cancer pain. Geographically, North America is expected to lead the cancer pain market. The presence of market leaders in the region, well-developed healthcare infrastructure, and enhanced healthcare spending contribute to the growth of the cancer pain market in the region. However, Asia Pacific is expected to record a high CAGR growth in the cancer pain market during the forecast period, owing to the growing awareness among people, and increased government spending on providing enhanced healthcare services to the people. China, Brazil, and India are expected to drive strong growth in the cancer pain market as a result of increasing investments by the government to enhance the healthcare facilities.
Request to View Sample of Research Report @ https://www.persistencemarketresearch.com/samples/13528
The leading players in the cancer pain market include Pfizer, Inc., Purdue Pharma, Mallinckrodt Pharmaceuticals, Teva Pharmaceuticals, Eli Lilly and Company, Johnson & Johnson, Endo Pharmaceuticals Inc., BioDelivery Sciences, ProStrakan Group, Sanofi S.A., and Grunenthal Group, among other significant global market players.